Albuterol tablets
Pro Research Analysisby 
Searched over 200M research papers for "albuterol tablets"
Albuterol Tablets: Efficacy, Safety, and Pharmacokinetics
Introduction to Albuterol Tablets
Albuterol sulfate, a selective beta-2-adrenergic bronchodilator, is commonly used to treat bronchial asthma in both adults and children. Available in various formulations, including tablets and syrups, albuterol provides relief from bronchospasm by relaxing the muscles in the airways and increasing airflow to the lungs.
Efficacy of Albuterol Tablets in Children
Extended-Release Albuterol Tablets
Extended-release albuterol tablets have been shown to be effective in children aged 6 to 12 years. A study involving 157 patients demonstrated that extended-release albuterol tablets significantly improved pulmonary function and reduced asthma symptoms compared to placebo. The primary efficacy parameter, the area under the curve (AUC) for FEV1, was significantly greater in the albuterol group, indicating better lung function . Additionally, both physicians' and patients' evaluations favored the albuterol group, and no serious treatment-related adverse events were reported .
Comparison with Syrup Formulation
In a comparative study, albuterol syrup was found to be more effective than tablets in terms of pulmonary function improvement and the need for additional medications. The syrup formulation reached its maximum effect at four hours and lasted for six hours, whereas the tablet's effect peaked at two hours and diminished after five hours . Despite the higher efficacy of the syrup, the tablet form remains a viable option, especially for those who prefer tablet administration.
Pharmacokinetics and Bioavailability
Absorption and Bioavailability
Albuterol is rapidly absorbed from both tablet and syrup formulations, with maximum drug concentrations achieved between 1.8 to 2.0 hours post-administration. The bioavailability of albuterol from tablet formulations is equivalent to that from a solution, ensuring consistent therapeutic effects . Additionally, food intake has minimal impact on the absorption of albuterol from repeat-action tablets, although it may delay the time to peak plasma concentration by about one hour .
Extended-Release vs. Conventional Tablets
Extended-release formulations, such as Proventil Repetabs and Volmax, offer the advantage of twice-daily dosing, which can improve patient compliance. Studies have shown that extended-release formulations provide a more controlled release of albuterol, with less peak-trough fluctuation compared to conventional tablets 56. This controlled release is particularly beneficial for managing nocturnal asthma symptoms.
Safety and Tolerance
Albuterol tablets are generally well-tolerated, with no significant differences in adverse events between different formulations. The most common side effects include increased heart rate and mild tremors, which are consistent with the drug's beta-2-adrenergic activity 12. Long-term studies have confirmed the safety of both conventional and extended-release albuterol tablets, with no clinically meaningful changes in vital signs or electrocardiograms 16.
Conclusion
Albuterol tablets, both in conventional and extended-release forms, are effective and safe for treating bronchial asthma in children and adults. While the syrup formulation may offer superior efficacy in some cases, the convenience of tablet administration and the controlled release of extended-release formulations make albuterol tablets a valuable option in asthma management. The consistent bioavailability and minimal impact of food on absorption further enhance their suitability for regular use.
Sources and full results
Most relevant research papers on this topic
Extended-release albuterol in the treatment of 6- to 12-year-old asthmatic children.
Extended-release albuterol tablets (4 mg) effectively improved pulmonary function and asthmatic symptoms in children aged 6-12 years, with no serious treatment-related adverse events.
DOI